AC430
Product Specifications
CAS Number
1361415-84-0
Target
Others, JAK
Related Pathways
JAK/STAT signaling, Chromatin/Epigenetic, Tyrosine Kinase/Adaptors, Angiogenesis, Stem Cells, Others
Bioactivity
AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg/kg/day.
Smiles
N(C=1C2=C(N=C([C@@H](O)C3=CC=C(F)C=C3)N1)C=CC=C2)C=4C=C(C)NN4
Molecular Formula
C19H16FN5O
Molecular Weight
349.36
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15238963 1 Vial
Lentiviral mouse Cfh shRNA (UAS) - Lentiviral mouse Cfh shRNA (UAS) plasmid
Sign In for Pricing
View Details 
MBS6307227-01 0.1 mL
HMGA1, CT (HMGA1, HMGIY, High mobility group protein HMG-I/HMG-Y, High mobility group AT-hook protein 1, High mobility group protein R) (MaxLight 550)
Sign In for Pricing
View Details MBS6307227-02 5x 0.1 mL
HMGA1, CT (HMGA1, HMGIY, High mobility group protein HMG-I/HMG-Y, High mobility group AT-hook protein 1, High mobility group protein R) (MaxLight 550)
Sign In for Pricing
View Details 